Biofrontera (NASDAQ:BFRI – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.31), FiscalAI reports. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%. The firm had revenue of $9.07 million for the quarter, compared to analyst estimates of $8.50 million.
Here are the key takeaways from Biofrontera’s conference call:
- Positive Sentiment: FDA approval of Ameluz for superficial basal cell carcinoma gives Biofrontera a second U.S. indication and a non-surgical treatment option using lamps already in dermatology offices. The company expects a full commercial launch in the first quarter of 2027.
- Positive Sentiment: U.S. Customs cleared the redesigned RhodoLED XL-C from the ITC exclusion order, and Biofrontera says remediation has reduced the share of Ameluz sales affected by the order from about 25% to 10%. The company expects field remediation to be substantially complete by the end of the second quarter of 2027, though appeals remain pending.
- Positive Sentiment: Third-quarter revenue rose 29.8% year over year to $9.1 million, with Ameluz tube volume up about 23%; gross margin improved to 74.4% from 70.7%. Management cautioned that much of the volume growth reflected orders brought forward ahead of the ITC order taking effect.
- Positive Sentiment: Biofrontera submitted an application to expand Ameluz use to actinic keratosis on the extremities, neck, and trunk, with an FDA decision date of August 5, 2027. The company says approval could extend treatment to larger body areas using its existing lamps and sales force.
- Negative Sentiment: The company reported $3.2 million in cash at quarter-end and disclosed substantial doubt about its ability to continue as a going concern for at least 12 months. Its mitigation plans include revenue growth, a working credit line, a conditional $1 million divestiture milestone, and potential additional capital; management said these plans have not alleviated the doubt, and the company does not currently meet Nasdaq’s minimum stockholders’ equity requirement.
Biofrontera Stock Down 24.4%
Shares of NASDAQ BFRI traded down $0.23 during midday trading on Friday, hitting $0.70. 875,774 shares of the company’s stock were exchanged, compared to its average volume of 148,265. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. Biofrontera has a twelve month low of $0.55 and a twelve month high of $1.66. The company has a market cap of $10.40 million, a PE ratio of -1.56 and a beta of 0.88. The firm’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.03.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on BFRI
Biofrontera Company Profile
Biofrontera Inc. is a biopharmaceutical company focused on dermatology and the commercial development of prescription products for treating skin conditions. Its business is primarily centered on the U.S. market. The company’s main product is Ameluz, a topical gel containing aminolevulinic acid hydrochloride. It is used with Biofrontera’s BF-RhodoLED light device in photodynamic therapy to treat certain actinic keratoses, precancerous lesions that can develop on sun-damaged skin. Biofrontera’s products combine a topical treatment with a specialized light source, which activates the treatment during a clinical procedure.
Read More
- Five stocks we like better than Biofrontera
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
